Ireland
--:--IST
Recruiting Observational

Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging

NCT07602010 · tracked via the Priya Life Science Norway tracker
Phase
Observational
Started
2026-04-22
Last updated
2026-05-22

Condition(s) studied

Bladder CancerUrothelial Carcinoma (UC)Muscle Invasive Bladder Cancer (MIBC)Non Muscle Invasive Bladder Cancer

Study summary

This prospective diagnostic accuracy study compares computed tomography (CT) and multiparametric magnetic resonance imaging (MRI) using the Vesical Imaging-Reporting and Data System (VI-RADS) for local staging of newly diagnosed bladder cancer. All participants undergo both imaging modalities prior to transurethral resection of the bladder tumor (TURBT) or cystectomy. Histopathology serves as the reference standard.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Newly diagnosed bladder cancer on cystoscopy * Planned TURBT or cystectomy within 6 weeks * Eligible for both CT and MRI within 6 weeks * Written informed consent provided Exclusion Criteria: * Contraindications to MRI or iodinated contrast media * Prior treatment for bladder cancer * Pregnancy * Non-malignant bladder lesions * Tumors located in bladder diverticula

Primary outcome measure(s)

  • Diagnostic Accuracy for Detection of Muscle-Invasive Bladder Cancer (≥T2) — From imaging to final histopathological reference standard (up to 12 months)
    The primary outcome is the diagnostic accuracy of multiparametric magnetic resonance imaging (MRI) using the Vesical Imaging-Reporting and Data System (VI-RADS) compared with contrast-enhanced computed tomography (CT) for the detection of muscle-invasive bladder cancer (pathological stage ≥T2). Sensitivity and specificity will be calculated using histopathology from transurethral resection of the bladder tumor, re-TURBT, and/or cystectomy as the reference standard.

Trial sites (1)

FacilityCityRegionStatus
Oslo University Hospital Oslo Norway Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07602010 on ClinicalTrials.gov ↗ ← All trials in Norway